Hope Hp-GC Project-Program Implementation for Primary and Secondary Prevention of Gastric Cancer in Latin America.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uribe Javier, Portillo-Miño José Darío, Latorre Gonzalo, Reyes-Placencia Diego, Pizarro Mauricio, Vargas José Ignacio, Espino Alberto, Jure Camila, Pizarro Margarita, Bofill Gabriela, Silva Felipe, Palacios Nilton, Díaz-Garrido Natalia, Huidobro Laura, Araya Raúl, Ledesma Sergio, Otero William, Otero Lina, Remes-Troche José M, Campos Christian, Largacha Monserrate, Varas Oscar, Cabrera Dacio, Piscoya Alejandro, Ramírez Juan, Laudanno Oscar, Esteves Sebastián, Cifuentes Sandra, García Eduardo, María-Guzmán Ana, Morgan Douglas, Espinoza Manuel, Shah Shailja C, Park Jin Young, Camargo M Constanza, Riquelme Arnoldo, Task Force HOPE Hp‐GC Project Consortium
Аннотация
METHODS: This study involved two strategies: (a) primary prevention for screen-and-treat H. pylori infection among individuals aged 30-39 years (n = 7500, 500 in 15 sites), and (b) primary and secondary prevention for individuals aged 40-75 years (n = 9600, 600 in 16 sites) with tiered risk stratification using an algorithm developed and validated in Chile (Gastrocalc: priority 1 to 6; age, sex, hypertension, IgG H. pylori, pepsinogen I and II, and Gastrin-17b), and high-quality esophagogastroduodenoscopy (EGD) evaluation.
RESULTS: Pilot phases were successfully conducted in Chile and Colombia during 2023-2025. In Chile (Molina), 4152 asymptomatic individuals were tested with H. pylori prevalence of 46% (n = 113/246) in 2023, 34% (n = 504/1484) in 2024, and 32% (n = 609/1904) in 2025. The H. pylori prevalence among individuals aged 30-39 years (592/4152; 14.3%) was 37.8%. In Colombia, 1250 asymptomatic individuals were screened across four regions; in 2025, the prevalence of H. pylori among individuals aged 30-39 years was 69% (n = 895/1250). The validation of Gastrocalc included 866 individuals from 5 regions in Chile. The algorithm successfully identified 80.6% of OLGA III-IV patients and 100% of GC patients (Priority 1-4). Other countries will start activities in 2026.
CONCLUSIONS: This pioneering study will advance understanding and feasibility of urgently needed primary and secondary prevention for GC in Latin America.